gamma delta T cells possess cytotoxic anti-tumor activity mediated by production of pro-inflammatory cytokines, direct cytotoxic activity and regulation of the biological functions of other cell types. Hence, these features have prompted the development of therapeutic strategies in which gamma delta T cells- agonists or ex vivo-expanded gamma delta T cells are administered to tumor patients. Several studies have shown that gamma delta T cells are an important component of tumor-infiltrating lymphocytes in patients affected by different types of cancer and a recent analysis of ~18,000 transcriptomes from 39 human tumors identified tumor-infiltrating gamma delta T cells as the most significant favourable cancer-wide prognostic signature. However, the complex and intricate interactions between tumor cells, tumor microenvironment and tumor-infiltrating immune cells results in a balance between tumor-promoting and tumor-controlling effects and gamma delta T cells functions are often diverted or impaired by immunosuppressive signals originating from the tumor microenvironment. This review focuses on the dangerous liason between gamma delta T cells and tumoral microenviroment and raises the possibility that strategies capable to reduce the immunosuppressive environment and increase the cytotoxic ability of gamma delta T cells may be the key factor to improve their utilization in tumor immunotherapy.
No takes yet. Share an insight, caveat, or question.
Presti et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: